EDP Sciences logo
Rechercher
Menu
Tous les numéros Volume 24 / Numéro 4 (2012) Ann Toxicol Anal, 24 4 (2012) 177-183 Références
Open Access
Numéro
Ann Toxicol Anal
Volume 24, Numéro 4, 2012
Page(s) 177 - 183
DOI https://doi.org/10.1051/ata/2012024
Publié en ligne 12 mars 2013
  1. Byakika-Kibwika P, Lamorde M, Kalemeera F, D’Avolio A, Mauro S, Di Perri G ,Ryan M, Mayanja-Kizza H, Khoo S, Back D, Boffito M, Merry C. Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2008; 62(5): 1113–1117. [CrossRef] [PubMed] [Google Scholar]
  2. Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, Hoover DR, Hanson J, Elul B, Ayaba A, Ellerbrock T, Rukundo A, Shumbusho F, Nash D, Mugabo J, Assimwe A. Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr. 2009; 52(1): 49–55. [CrossRef] [PubMed] [Google Scholar]
  3. Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnuovo F, Gargiulo F, Manca N, Carosi G. Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. Aids Patient Care STDS. 2007; 21(2): 92–99. [CrossRef] [PubMed] [Google Scholar]
  4. Re MC, Bon I, Monari P, Gorini R, Schiavone P, Gibellini D, La Placa M. Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance. New Microbiol. 2003; 26(4): 405–413. [Google Scholar]
  5. Peters BS, Conway K. Therapy for HIV: past, present, and future. Adv Dent Res. 2011; 23(1): 23–27. [CrossRef] [PubMed] [Google Scholar]
  6. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS. 2004; 18(18): 2391–2400. [PubMed] [Google Scholar]
  7. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005; 15(1): 1–5. [CrossRef] [PubMed] [Google Scholar]
  8. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007; 8(2): 86–91. [CrossRef] [PubMed] [Google Scholar]
  9. Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis. 2009; 199(6): 872–880. [CrossRef] [PubMed] [Google Scholar]
  10. Donnerer J, Kronawetter M, Kapper A, Haas I, Kessler HH. Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology. 2003; 69(4): 197–204. [CrossRef] [PubMed] [Google Scholar]
  11. Schuman M, Schneider S, Omes C, Wennig R, Fundira L, Tayari JC, Arendt V. HPLC analysis of generic antiretroviral drugs purchased in Rwanda. Bull Soc Sci Med Grand Duche Luxemb. 2005; (3): 317–325. [PubMed] [Google Scholar]
  12. Rebiere H, Mazel B, Civade C, Bonnet PA. Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850(1-2): 376–383. [CrossRef] [PubMed] [Google Scholar]
  13. Taylor PJ, Tai CH, Franklin ME, Pillans PI. The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs. Clin Biochem. 2011; 44(1): 14–20. [CrossRef] [PubMed] [Google Scholar]
  14. Notari S, Mancone C, Alonzi T, Tripodi M, Narciso P, Ascenzi P. Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 863(2): 249–257. [CrossRef] [PubMed] [Google Scholar]
  15. Meesters RJ, van Kampen JJ, Reedijk ML, Scheuer RD, Dekker LJ, Burger DM, Hartwig NG, Osterhaus AD, Luider TM, Gruters RA. Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Anal Bioanal Chem. 2010; 398(1): 319–328. [CrossRef] [PubMed] [Google Scholar]
  16. Chiang JF, Hsiao YT, Ko WK, Wu SM. Analysis of multiple abused drugs and hypnotics in urine by sweeping CE. Electrophoresis. 2009; 30(14): 2583–2589. [CrossRef] [PubMed] [Google Scholar]
  17. Steppe M, Prado MS, Tavares MF, Kedor-Hackmann ER, Santoro MI. Determination of cephalexin in oral suspensions by micellar electrokinetic chromatography. Journal of capillary electrophoresis and microchip technology. 2002; 7(3-4): 81–86. [PubMed] [Google Scholar]
  18. Yang YH, Wu WY, Yeh HH, Chen SH. Simultaneous determination of cefepime and vancomycin in plasma and cerebrospinal fluid by MEKC with direct sample injection and application for bacterial meningitis. Electrophoresis. 2007; 28(11): 1788−1797. [CrossRef] [PubMed] [Google Scholar]
  19. Znaleziona J, Petr J, Maier V, Knob R, Horakova J, Smetanova D, Sevcik J. Capillary electrophoresis as a verification tool for immunochemical drug screening. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007; 151(1): 31–36. [CrossRef] [PubMed] [Google Scholar]
  20. Marini RD, Rozet E, Montes ML, Rohrbasser C, Roht S, Rheme D, Bonnabry P, Schappler J, Veuthey JL, Hubert P, Rudaz S. Reliable low-cost capillary electrophoresis device for drug quality control and counterfeit medicines. J Pharm Biomed Anal. 2010; 53(5): 1278–1287. [CrossRef] [PubMed] [Google Scholar]
  21. Sekar R, Azhaguvel S. Simultaneous determination of HIV-protease inhibitors lamivudine and zidovudine in pharmaceutical formulations by micellar electrokinetic chromatography. J Pharm Biomed Anal. 2005; 39(3-4): 653–660. [CrossRef] [PubMed] [Google Scholar]
  22. Sekar R, Azhaguvel S. MEKC determination of antiretroviral reverse transcriptase inhibitors lamivudine, stavudine, and nevirapine in pharmaceutical formulations. Chromato- graphia. 2008; 67(5): 389–398. [CrossRef] [Google Scholar]
  23. Fan B, Stewart JT. Determinations of zidovudine/didanosine/ nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography. J Pharm Biomed Anal. 2002; 30(4): 955–960. [CrossRef] [PubMed] [Google Scholar]
  24. Fan B, Stewart JT. Determination of lamivudine/ didanosine/nevirapine in human serum using capillary zone electrophoresis. J Capill Electrophor Microchip Technol. 2002; 7(5-6): 103–106. [PubMed] [Google Scholar]
  25. Pereira EA, Micke GA, Tavares MF. Determination of antiretroviral agents in human serum by capillary electrophoresis. J Chromatogr A. 2005; 1091(1-2): 169–176. [CrossRef] [PubMed] [Google Scholar]
  26. Tuan ND, Gutleben W, Scherer K, Stoiber H, Falkensammer B, Dierich MP, Zemann A. Simultaneous separation of fifteen approved protease and reverse transcriptase inhibitors for human immunodeficiency virus therapy by capillary electrophoresis. Electrophoresis. 2003; 24(4): 662–670. [CrossRef] [PubMed] [Google Scholar]
  27. Fritz JS. The role of organic solvents in the separation of nonionic compounds by capillary electrophoresis. Electrophoresis. 2003; 24(10): 1530–1536. [CrossRef] [PubMed] [Google Scholar]
  28. Nicolas O, Farenc C, Bressolle F. Stratégie de validation de méthodes de dosage en bioanalyse en vue d’études pharmacocinétiques et toxicologiques. Ann Toxicol Anal. 2004; 16(2): 118–127. [CrossRef] [EDP Sciences] [Google Scholar]